Shire plc is considering taking its neuroscience business public as part of a strategic review, which is expected to be complete by the end of 2017.

The company made the announcement in its second-quarter earnings release, reporting $1.13 billion, or $3.73 per American depositary share, in non-GAAP income for the three months ended June 30. This would compare to the $772.6 million, or $3.38 per ADS, booked in the second quarter of 2016.

The S&P Capital IQ normalized EPS consensus estimate for the second quarter was $3.53.

Shire generated $3.75 billion in second-quarter revenues, an increase of 54% year over year thanks to the inclusion of legacy Baxalta sales. Shire's neuroscience division generated $635.4 million in second-quarter revenues, a decrease from $655.2 million on a yearly basis given generic competition for Adderall XR.

Shire booked $240.3 million, or 79 cents per ADS, in second-quarter GAAP income, which compares to a loss of $162.1 million, or 71 cents per ADS, in the same quarter of 2016.

The company said it will now target $14.80 to $15.20 in full-year 2017 non-GAAP earnings per ADS and $5.65 to $6.05 in GAAP earnings per ADS. This would compare to the previous guidance of $14.60 and $15.20 in non-GAAP and $6.95 to $7.55 in GAAP EPS per ADS.

The S&P Capital IQ normalized EPS consensus estimate for 2017 is $14.85.